Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOM613 in Severe COVID-19
NCT05212532Phase 1Unknown
- Sponsor
- EOM Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Feb 2022
- Modality
- Peptides, Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of EOM613 in coronavirus disease 2019 (COVID-19), COVID-19 pneumonia and acute respiratory distress syndrome (ARDS) (2 cohorts), sponsored by EOM Pharmaceuticals. Primary endpoints: Blood Urea Nitrogen at Day 11, Blood Creatinine at Day 11 and 4 more. Status: unknown.
02
Drugs
EOM613
03
Conditions
coronavirus disease 2019 (COVID-19)COVID-19 pneumoniaacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05212532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212532.